Joakim Nyberg

Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors

Using forest plots to interpret covariate effects in pharmacometric models

Properties of the full random‐effect modeling approach with missing covariate data

Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials

Machine learning and pharmacometrics for prediction of pharmacokinetic data: differences, similarities and challenges illustrated with rifampicin

Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations

A quantitative approach to the choice of number of samples for percentile estimation in bootstrap and visual predictive check analyses

An introduction to the full random effects model